<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03510767</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-B3525-I-01</org_study_id>
    <nct_id>NCT03510767</nct_id>
  </id_info>
  <brief_title>A Study of TQ-B3525 on Tolerance and Pharmacokinetics</brief_title>
  <official_title>A Phase I Study of TQ-B3525 on Tolerance and Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the pharmacokinetic characteristics of TQ-B3525 in the human body, recommend a
      reasonable regimen for subsequent research.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicities (DLT)</measure>
    <time_frame>Baseline up to 28 days</time_frame>
    <description>DLT: An adverse event occurring after initiation of TQ-B3525 that met any following criteria:
＞=Grade 3 of non-hematology toxicity
Grade 4 hematology toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Baseline up to 28 days</time_frame>
    <description>MTD was defined as the highest dose level studied for which the incidence of first cycle DLT was ＜ 33%.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Relapsed or Refractory Lymphoma or Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>TQ-B3525</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B3525</intervention_name>
    <description>TQ-B3525 p.o. qd</description>
    <arm_group_label>TQ-B3525</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory lymphoma or advanced solid tumor that diagnosed Pathologically
             or cytologically diagnosed

          -  ECOG PS≤1

          -  Adequate blood cell counts, kidney function and liver function

          -  Patients should participate in the study voluntarily and sign informed consent

        Exclusion Criteria:

          -  Patients with immunodeficiency, including HIV positive or other acquired, congenital
             immunodeficiency disease, or organ transplant history

          -  Hypertension (systolic BP ≥150 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by
             one medication

          -  Hepatitis B virus patients with active replication (DNA&gt; 500 cps / mL), hepatitis C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huaqing Wang, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>People's Hospital of Tianjin Tianjin,China,300121</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wenqi Jiang, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China, 510060</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huaqing Wang, doctor</last_name>
    <phone>+86-022-022-2757483</phone>
    <email>huaqingw@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>People's Hospital of Tianjin</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huaqing Wang, doctor</last_name>
      <phone>+86-022-022-2757483</phone>
      <email>huaqingw@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

